Tag Archives: Johnson & Johnson

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

South Korea’s Celltrion Inc. (Incheon) gets EU green light for Herceptin biosimilar

The News: Celltrion Inc. said on February 14, 2018 that it has received approval to sell its replica version of Roche Holding AG’s (Basel CHE) breast-cancer blockbuster Herceptin in Europe…. Read more »

From across the pond, 2017’s brightest European biotech stars; perhaps under US’s radar, but still ready to soar?

Many said good riddance to 2016 for biotech and pharma; things could only get better this year–and the European industry didn’t disappoint, says Labiotech.eu, the quintessential industry observer and news… Read more »

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »

Idorsia leaps 45% in market debut; Actelion spinoff looks like sure bet with J&J backing to boot. How to invest.

Idorsia Ltd. (Allschwil CHE), the research-based spin-out from Actelion following the latter’s $30 billion acquisition by Johnson & Johnson (New Brunswick NJ), which has now been completed, started trading on… Read more »

IPO Alert: Actelion founders launch startup on $1.5 billion J&J payday: call your broker, soon

Steve’s Take: If ever there was a “story” biotech IPO worth grabbing even a tiny piece of, this is it. First, the story: Two decades ago Jean-Paul and Martine Clozel… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Trump and pharma execs make nice; what, Sen. Sanders too?

The News: Last week (January 30, 2017), President Trump promised some of the nation’s top drug-company executives in a meeting at the White House that he would shrink Food and… Read more »